Impact of perioperative blood transfusion on survival of patients undergoing laparoscopic gastrectomy for gastric cancer

Rong Gui, Hao Tang, Meng Gao, Jing Liu, Rong Huang, Guosheng Zhao, Jinqi Ma, Mengqing Yi, Fengxia Liu, Yunfeng Fu
The Third Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China

Summary

Purpose: Previous studies have suggested that perioperative blood transfusion is associated with poor prognosis in patients undergoing radical gastrectomy for gastric cancer. The purpose of this study was to evaluate the impact of blood transfusion on the long-term survival of such patients.

Methods: Short- and long-term outcomes were retrieved from a prospectively collected database of patients who underwent laparoscopic gastrectomy with radical intent for gastric cancer.

Results: A total of 309 patients who underwent laparoscopic radical gastrectomy were evaluated. Sixty-one (19.7%) received blood transfusions during or within 30 days after gastrectomy. These patients were typically older, had lower preoperative hemoglobin levels, had a more advanced cancer stage, had more than two comorbidities, had a higher rate of postoperative 30-day complications, and had a higher conversion rate. The overall survival (OS) (p=0.040) and disease-free survival (DFS) (p=0.004) were significantly decreased in patients who received blood transfusions. Multivariate analysis revealed that perioperative blood transfusion was not independently associated with decreased OS and DFS but that cancer stage and having more than two comorbidities were independent risk factors.

Conclusion: Perioperative blood transfusion was associated with decreased OS and DFS in this patient series, but this apparently reflected the relatively poor medical condition of these patients requiring gastrectomy and was not a causative relationship.

Key words: blood transfusion, gastric cancer, laparoscopic gastrectomy, minimally invasive surgery

Introduction

Perioperative blood transfusion has been associated with decreased OS and DFS of patients who undergo radical gastrectomy for gastric cancer [1-3]. Some studies have suggested a causative relationship and an impact on the immune system, resulting in increased immunosuppression [4-6]. Studies have not shown a difference in the long-term outcomes between patients undergoing laparoscopic radical gastrectomy and those undergoing open radical gastrectomy for gastric cancer [7-17]. However, compared with the open approach, laparoscopic gastrectomy for gastric cancer was found to be associated with less immunosuppression, less blood loss, and less need for blood transfusion [7-17].

The aim of this study was to evaluate the risk factors for perioperative blood transfusion and its impact on long-term outcomes in patients undergoing laparoscopic radical gastrectomy for gastric cancer.
Methods

All patients who underwent laparoscopic radical gastrectomy for gastric cancer between December 2008 and December 2015 were included. All operations were performed by two senior surgeons. Patient age, sex, body mass index, American Society of Anesthesiologists score, medical comorbidities, tumor location, TNM stage, conversion to open gastrectomy, postoperative 30-day mortality, postoperative 30-day morbidity, and pathological data were collected directly from medical records. Long-term OS and DFS data were collected from our outpatient clinic and from personal contacts when necessary. OS was assessed from the date of surgery until the last follow-up or death from any cause. DFS was calculated from the date of surgery until the date of cancer recurrence or death from any cause.

Perioperative blood transfusions included all those given on the day of operation or during the postoperative 30-day hospitalization. Preoperative evaluation included upper gastrointestinal endoscopy, endoscopic ultrasonography, computed tomographic (CT) scans of the brain, chest, and abdomen; and ultrasonography of the abdomen. Positron emission tomography-CT (PET-CT) and bone scans were performed in selected cases when necessary. The TNM staging of gastric cancer (7th Edn), the Japanese Gastric Cancer Association, and the American Joint Committee on Cancer classification were applied [18-20]. The staging of patients with surgery before 2009 was recalculated to match the more recent TNM classification. Perioperative mortality included deaths occurring within 30 days of gastrectomy. Postoperative morbidity was graded following the Clavien–Dindo classification. Major complications included grades 3, 4, and 5; minor complications included grades 1 and 2. Details of the Clavien–Dindo classification have been reported elsewhere [21-33].

Following discharge, patients were followed up as outpatients every 3 months for the first 2 years, every 6 months for the next 3 years, and at either 6 months or annually thereafter. At each visit, they underwent physical examination and general blood and serum tests. The 6-month follow-up alternated between thoracic and abdominal CT or abdominal ultrasonography and chest radiography. Disease recurrence was defined as radiologically or pathologically confirmed locoregional or distant metastasis, and the time of diagnosis was determined by the interval between surgery and the last follow-up. The last scheduled study follow-up was August 2016. The study was approved by the institutional review board of our institution. The need for informed consent from patients was waived because this was a retrospective study.

Statistics

Statistical analysis was performed using SPSS 14.0 (SPSS Inc., Chicago, IL, USA). Normally distributed data were presented as mean and standard deviation (SD), and differences were analyzed by Student’s t-test. Data that were not normally distributed were expressed as median and range, and differences were compared by the Mann-Whitney U test. Differences of semiquantitative results were analyzed by the Mann-Whitney U test. Differences of qualitative results were analyzed by the chi-square or Fisher exact test where appropriate. The survival rates were estimated by the Kaplan-Meier method, and the significance of differences was deter-

Table 1. Clinical and pathological characteristics of the two groups

<table>
<thead>
<tr>
<th></th>
<th>No transfusion (n=248)</th>
<th>Transfusion (n=61)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years (range)</td>
<td>59 (41-75)</td>
<td>67 (57-81)</td>
<td>0.010</td>
</tr>
<tr>
<td>Gender (male:female)</td>
<td>149:99</td>
<td>55:26</td>
<td>0.700</td>
</tr>
<tr>
<td>Preoperative hemoglobin level (g/L) (range)</td>
<td>117 (81-158)</td>
<td>93 (74-148)</td>
<td>0.026</td>
</tr>
<tr>
<td>Number of comorbidities</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>100</td>
<td>44</td>
<td>0.465</td>
</tr>
<tr>
<td>1</td>
<td>39</td>
<td>9</td>
<td>1.000</td>
</tr>
<tr>
<td>2</td>
<td>18</td>
<td>5</td>
<td>1.000</td>
</tr>
<tr>
<td>≥3</td>
<td>1</td>
<td>3</td>
<td>0.051</td>
</tr>
<tr>
<td>ASA score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>193</td>
<td>46</td>
<td>0.687</td>
</tr>
<tr>
<td>II</td>
<td>48</td>
<td>13</td>
<td>0.751</td>
</tr>
<tr>
<td>III</td>
<td>7</td>
<td>2</td>
<td>1.000</td>
</tr>
<tr>
<td>Retrieved lymph nodes</td>
<td>17 (15-29)</td>
<td>14 (16-27)</td>
<td>0.189</td>
</tr>
<tr>
<td>Residual tumor (R0/R1/R2)</td>
<td>248/0/0</td>
<td>61/0/0</td>
<td>1.000</td>
</tr>
<tr>
<td>Histological differentiation</td>
<td></td>
<td></td>
<td>0.625</td>
</tr>
<tr>
<td>Differentiated</td>
<td>146</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>Undifferentiated</td>
<td>102</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>Pathological TNM stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>97</td>
<td>2</td>
<td>0.000</td>
</tr>
<tr>
<td>II</td>
<td>77</td>
<td>26</td>
<td>0.086</td>
</tr>
<tr>
<td>III</td>
<td>74</td>
<td>55</td>
<td>0.000</td>
</tr>
</tbody>
</table>
Impact on survival of perioperative blood transfusion in gastric cancer patients

mined by the log-rank test. Univariate analyses were performed to identify prognostic variables related to OS and DFS and those that were found to be significant (p<0.10) were selected for inclusion in a multivariate Cox proportional hazard regression model. Adjusted hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were calculated. A p value < 0.05 was considered statistically significant.

Results

During the study period, 309 patients underwent laparoscopic radical gastrectomy procedures for gastric cancer and were included in this study. Sixty-one patients (19.7%) received blood transfusions on the day of gastrectomy or during the 30 days of hospitalization following surgery. Compared with patients who did not receive perioperative blood transfusions, patients who received blood transfusions were typically older, had a lower preoperative hemoglobin level, had more than two comorbidities, had a more advanced cancer stage, had a higher rate of conversion to open surgery, and had a higher rate of postoperative 30-day complications (Table 1 and Table 2).

The median follow-up time was 38 months, and 5 patients (3 in the transfusion group and 2 in the no transfusion group) were lost to follow-up at various time points. Both OS and DFS were significantly decreased in patients who received transfusions (Figures 1 and 2). Cancer stage and more than two comorbidities were found to be independently associated with both OS (Tables 3 and 4) and DFS (Tables 5 and 6). Receiving perioperative blood transfusions was not found to be independently associated with the risk of decreased OS or DFS.

Table 2. Surgical outcomes of the two groups

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>No transfusion (n=248)</th>
<th>Transfusion (n=61)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of gastrectomy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total gastrectomy</td>
<td>97</td>
<td>22</td>
<td>0.661</td>
</tr>
<tr>
<td>Distal gastrectomy</td>
<td>151</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td>Conversion to open surgery</td>
<td>12</td>
<td>10</td>
<td>0.004</td>
</tr>
<tr>
<td>Operative time, min (range)</td>
<td>180 (140-290)</td>
<td>200 (160-280)</td>
<td>0.102</td>
</tr>
<tr>
<td>Estimated blood loss, ml (range)</td>
<td>210 (160-490)</td>
<td>220 (180-440)</td>
<td>0.098</td>
</tr>
<tr>
<td>Length of postoperative stay, days (range)</td>
<td>10 (7-29)</td>
<td>13 (7-25)</td>
<td>0.078</td>
</tr>
<tr>
<td>Postoperative 30-day complications</td>
<td>19</td>
<td>13</td>
<td>0.002</td>
</tr>
<tr>
<td>Major complications</td>
<td>4</td>
<td>2</td>
<td>0.879</td>
</tr>
<tr>
<td>Minor complications</td>
<td>15</td>
<td>11</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. Overall survival curve in the two groups of patients with gastric carcinoma (p=0.040).

Figure 2. Disease-free survival curve in the two groups of patients with gastric carcinoma (p=0.004).
Impact on survival of perioperative blood transfusion in gastric cancer patients

Discussion

In our study, blood transfusion was associated with significantly poorer OS and DFS following laparoscopic radical gastrectomy for gastric cancer. Patients who received blood were typically older, had lower preoperative hemoglobin levels, had a more advanced cancer stage, had more than two comorbidities, had a higher rate of complications, and had a higher conversion rate. However, multivariate analysis did not find that blood transfusion was independently related to the risk of decreased OS or DFS. Differences in the demographic and clinical characteristics of the two patient groups might explain the differences in survival.

This study differs from other investigations on the effect of perioperative blood transfusion on OS and DFS in gastric cancer patients by its inclusion of only laparoscopic gastrectomy patients [1-6]. Furthermore, in our series, all surgical procedures were performed by the same two surgeons.

To the best of our knowledge, this is the first English language report to investigate the effects of perioperative blood transfusion on long-term OS and DFS outcomes in patients with laparoscopic gastrectomy for gastric cancer.

A possible cause of tumor recurrence in patients receiving perioperative blood transfusions during gastrectomy for gastric cancer is immunosuppression, resulting from both blood transfusion and the surgery itself. Previous reports have associated the decrease in tissue injury during laparoscopic gastrectomy compared with open gastrectomy with better preservation of the immune function [7-10]. Theoretically, producing less tissue injury could reduce the impact of perioperative blood transfusion on the immune system, with its consequent decrease in OS and DFS.

Intraoperative blood loss is often lower in laparoscopic than in open gastrectomy. A reduction in the blood transfusion rate is not a necessary consequence of lesser blood loss, but laparoscopic gastrectomy has been reported to reduce the number of units of perioperatively transfused blood as well as the number of patients receiving blood transfusions. In the present study, the rate of perioperative blood transfusions was relatively high and was probably related to both patient characteristics and the lack of standard guidelines for perioperative blood transfusion. However, comparative studies have shown less blood transfusion in laparoscopically-treated patients [7-12]. Perioperative blood transfusion has been shown to increase the risk of postoperative morbidity following open but not laparoscopic surgery.

Our study findings are in line with those that did not find a causal relationship between perioperative blood transfusion and worse prognosis following open gastrectomy. Previous reports suggested that the poor prognosis observed in gastric cancer patients who received perioperative blood transfusion was related to the circumstances that necessitated the transfusion and not to the transfusion per se [34-36].

Regarding conversion to open gastrectomy, laparoscopic gastrectomy procedures for gastric cancer have been associated with lower postop-

Table 3. Univariate analysis of 5-year overall survival of the 309 patients

<table>
<thead>
<tr>
<th>Variables</th>
<th>5-year overall survival %</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;65</td>
<td>55</td>
<td>0.127</td>
</tr>
<tr>
<td>≥65</td>
<td>41</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>50</td>
<td>0.122</td>
</tr>
<tr>
<td>Female</td>
<td>49</td>
<td></td>
</tr>
<tr>
<td>ASA score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>51</td>
<td>0.128</td>
</tr>
<tr>
<td>III</td>
<td>37</td>
<td></td>
</tr>
<tr>
<td>More than two comorbidities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>59</td>
<td>0.035</td>
</tr>
<tr>
<td>Yes</td>
<td>52</td>
<td></td>
</tr>
<tr>
<td>Type of gastrectomy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total gastrectomy</td>
<td>52</td>
<td>0.128</td>
</tr>
<tr>
<td>Distal gastrectomy</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>Pathological TNM stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>69</td>
<td>0.000</td>
</tr>
<tr>
<td>III</td>
<td>52</td>
<td></td>
</tr>
<tr>
<td>Histological differentiation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Differentiated</td>
<td>46</td>
<td>0.205</td>
</tr>
<tr>
<td>Undifferentiated</td>
<td>37</td>
<td></td>
</tr>
<tr>
<td>Major complication</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>54</td>
<td>0.059</td>
</tr>
<tr>
<td>Yes</td>
<td>41</td>
<td></td>
</tr>
<tr>
<td>Blood transfusion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>48</td>
<td>0.040</td>
</tr>
<tr>
<td>Yes</td>
<td>40</td>
<td></td>
</tr>
</tbody>
</table>

Table 4. Cox proportional hazards model for overall survival

<table>
<thead>
<tr>
<th>Variables</th>
<th>Hazard ratio (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage: I-II vs stage III</td>
<td>2.158 (1.269-4.870)</td>
<td>0.018</td>
</tr>
<tr>
<td>Comorbidities: Up to 2 vs &gt;2</td>
<td>2.510 (1.257-4.020)</td>
<td>0.021</td>
</tr>
</tbody>
</table>
Impact on survival of perioperative blood transfusion in gastric cancer patients

In this series, a greater proportion of patients who received transfusions experienced conversion to open surgery. The patients in this series who received transfusions had less favorable baseline characteristics compared with those who did not receive transfusions. Previous reports explained the lower survival rates among gastric cancer patients who received perioperative blood transfusions by the presence of a lower transfusion threshold in patients with underlying cardiovascular or pulmonary diseases. Moreover, an increase in the number of blood units given during surgery was associated with an increase in postoperative mortality. These studies suggest that avoiding the need for perioperative blood transfusion improves poor prognosis, irrespective of the existence of a causal relationship.

We showed a non-causal relationship between blood transfusion and prognosis in patients who underwent laparoscopic gastrectomy. Similar to reports of outcomes of open surgery, we found that the poor health of patients who received blood transfusions could explain their poor prognosis [4-6]. It has been suggested that improving surgical procedures might improve prognosis by reducing the need for blood transfusion. The advantages of laparoscopic gastrectomy that may be related to the need for blood transfusion are better preservation of immune function and reduced blood loss during surgery.

A limitation of our study was the decision to administer blood transfusions based on clinical and laboratory factors, without definitive guidelines regarding indications for transfusion. Accepted guidelines for blood transfusion should be followed to standardize the indications for blood transfusion and to avoid unnecessary transfusions. A controlled comparative study of open and laparoscopic surgery, with a larger number of patients, may show the impact of blood transfusion on long-term outcomes more clearly.

In summary, perioperative blood transfusion was associated with decreased OS and DFS in patients who underwent laparoscopic gastrectomy for gastric cancer. The association reflected the clinical condition of patients requiring surgery and was not a causal relationship.

Acknowledgements

We sincerely thank the patients, their families and our hospital colleagues who participated in this research.

Conflict of interests

The authors declare no conflict of interests.

<table>
<thead>
<tr>
<th>Table 5. Univariate analysis of 5-year disease-free survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variables</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Age, years</td>
</tr>
<tr>
<td>&lt;65</td>
</tr>
<tr>
<td>≥65</td>
</tr>
<tr>
<td>Gender</td>
</tr>
<tr>
<td>Male</td>
</tr>
<tr>
<td>Female</td>
</tr>
<tr>
<td>ASA score</td>
</tr>
<tr>
<td>I-II</td>
</tr>
<tr>
<td>III</td>
</tr>
<tr>
<td>More than two comorbidities</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>Type of gastrectomy</td>
</tr>
<tr>
<td>Total gastrectomy</td>
</tr>
<tr>
<td>Distal gastrectomy</td>
</tr>
<tr>
<td>Pathological TNM stage</td>
</tr>
<tr>
<td>I-II</td>
</tr>
<tr>
<td>III</td>
</tr>
<tr>
<td>Histological differentiation</td>
</tr>
<tr>
<td>Differentiated</td>
</tr>
<tr>
<td>Undifferentiated</td>
</tr>
<tr>
<td>Major complication</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>Blood transfusion</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>Yes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 6. Cox proportional hazards model for disease-free survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variables</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>Stage I-II vs stage III</td>
</tr>
<tr>
<td>N0-N1 vs N2-N3</td>
</tr>
</tbody>
</table>

erative morbidity, mortality, and similar survival outcomes compared with open gastrectomy procedures [7-9]. Nevertheless, recent evidence suggests a negative impact of conversion on long-term outcome in gastric cancer patients. Interestingly, in this series, a greater proportion of patients who received transfusions experienced conversion to open surgery.

The patients in this series who received transfusions had less favorable baseline characteristics compared with those who did not receive transfusions. Previous reports explained the lower
References


Impact on survival of perioperative blood transfusion in gastric cancer patients


